GlassScriptPhysician profile
Anita Sheth
NPI 1134173040
$5,151.29
in general payments reported to CMS, 2019-2025
23 companies · $271 in 2025
The $271 reported for 2025 was less than what a typical Pediatric Dermatology provider received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $39.12 · 2021: $2,524 · 2022: $808 · 2023: $699 · 2024: $339 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,137 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,137.04 |
| Education | $171.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,101.84 | 2019-2025 | Rinvoq |
| Regeneron Healthcare Solutions, INC. | $755.17 | 2019-2025 | Dupixent |
| Incyte Corporation | $461.88 | 2021-2025 | Opzelura |
| Almirall LLC | $318.78 | 2019-2025 | Klisyri, Seysara |
| Genzyme Corporation | $236.79 | 2021-2024 | |
| Janssen Biotech, INC. | $202.98 | 2021-2025 | Tremfya |
| Vyne Pharmaceuticals INC. | $172.17 | 2021 | |
| Lilly USA, LLC | $146.20 | 2020-2025 | Taltz, Ebglyss |
| Sun Pharmaceutical Industries INC. | $111.17 | 2022-2023 | Ilumya |
| Galderma Laboratories, L.P. | $90.71 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $84.40 | 2021 | |
| Sanofi-Aventis U.S. LLC | $81.03 | 2019 | |
| Pfizer INC. | $59.71 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $57.33 | 2019-2024 | Cabtreo |
| Organon LLC | $46.65 | 2025 | Vtama |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $39.26 | 2024-2025 | Bimzelx |
| Amgen INC. | $37.77 | 2022 | |
| Verrica Pharmaceuticals INC. | $35.86 | 2023 | Ycanth |
| Janssen Scientific Affairs, LLC | $35.64 | 2019 | |
| Mylan Pharmaceuticals INC. | $26.19 | 2019 | |
| Botanix Sb INC | $21.38 | 2025 | Sofdra |
| E.R. Squibb & Sons, L.L.C. | $15.05 | 2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $13.33 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anita Sheth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.